Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$47.46

0.09 (0.19%)

13:09
11/17/19
11/17
13:09
11/17/19
13:09

AstraZeneca says data shows Farxiga reduces risks in heart failure patients

AstraZeneca announced new data from five additional analyses of the landmark Phase III DAPA-HF trial, which showed that Farxiga reduced the risk of the primary composite outcome of worsening heart failure, or HF, defined as hospitalization or an urgent visit, or death from cardiovascular, or CV, causes versus placebo, when added to standard of care. DAPA-HF is the first outcomes trial with an SGLT2 inhibitor investigating the treatment of HF in patients with reduced ejection fraction, with and without type 2 diabetes, or T2D. The new analyses showed the consistency of these results across patient subgroups with and without T2D, an early onset of effects, and improvement in patient-reported outcomes of HF-related health status. These data were presented at the American Heart Association, or AHA, Scientific Sessions in Philadelphia. Elisabeth Bjork, senior VP, Head of Late-stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, said: "Heart failure affects approximately 64M people around the world and about half of those patients will die within five years of diagnosis. These new analyses from the DAPA-HF trial reinforce the science behind FARXIGA as clinically significant across heart failure patient populations and suggest the potential to improve the current standard of care for millions of these patients."

  • 18

    Nov

  • 07

    Dec

AZN AstraZeneca
$47.46

0.09 (0.19%)

11/05/19
JEFF
11/05/19
NO CHANGE
Target $75
JEFF
Buy
Jefferies sees nothing new in FibroGen short report
Jefferies analyst Michael Yee does not see "anything really new" in yesterday's short report on FibroGen. The report is all based on earlier small Phase II/III studies that are already known, as well as on studies in China/Japan, where the drug has recently been approved, Yee tells investors in a research note. Moreover, FibroGen partner AstraZeneca (AZN) has publicly stated it is comfortable with the data, adds Yee. He keeps a Buy rating on FibroGen shares with a $75 price target
11/10/19
PIPR
11/10/19
NO CHANGE
PIPR
Piper Jaffray sees approval for FibroGen's roxadustat, but still has concerns
Piper Jaffray analyst Danielle Brill maintained a Neutral rating and $42 price target on FibroGen (FGEN). After getting more color on the MACE data from a meeting with management, speaking to a lead investigator, and listening to AstraZeneca's (AZN) call, Brill continues to expect approval of the drug, but also sees aspects that will drive debate, and a lack of clarity until FDA briefing documents for an Ad Com panel are released next year, which could be 6-10 months from now depending on priority. The analyst also still questions whether the labeling for the drug, if it is approved, will include a black box safety warning.
11/12/19
JEFF
11/12/19
NO CHANGE
JEFF
Buy
Jefferies doesn't see 'anything new' in latest FibroGen short report
Jefferies analyst Michael Yee addressed some of the takeaways from "another short report" on FibroGen (FGEN), which he doesn't think includes "anything new." He has previously said that he expects ongoing "noise and confusion" about cardiovascular events in various populations, though he has talked to FibroGen, AstraZeneca (AZN) and many doctors and investigators, who "support a clear view of approval and safety here." The newest short report published on FibroGen highlights topics that are "generally known or mentioned in our previous reports," added Yee, who has a Buy rating on the shares.
11/15/19
GUGG
11/15/19
NO CHANGE
Target $228
GUGG
Buy
BeiGene price target raised to $228 from $205 at Guggenheim
Guggenheim analyst Michael Schmidt raised his price target for BeiGene (BGNE) to $228 from $205 saying FDA approval of Brukinsa over three months ahead of the action date provides additional validation of the company's strategy and ability to execute. He thinks Brukinsa's label in mantle cell lymphoma indicates a "potentially best-in-class" product profile with "nuanced differences" compared to AstraZeneca's (AZN) Calquence and "significantly better" than AbbVie's (ABBV) Imbruvica. The analyst maintains a Buy rating on BeiGene shares.

TODAY'S FREE FLY STORIES

IPG

Interpublic Group

$22.49

0.2 (0.90%)

, CMCSA

Comcast

$44.24

0.18 (0.41%)

08:00
12/09/19
12/09
08:00
12/09/19
08:00
Conference/Events
UBS to hold a conference »

Global TMT Conference…

IPG

Interpublic Group

$22.49

0.2 (0.90%)

CMCSA

Comcast

$44.24

0.18 (0.41%)

PTON

Peloton

$32.56

1.24 (3.96%)

IAC

IAC

$216.01

-0.54 (-0.25%)

VRTU

Virtusa

$44.69

0.99 (2.27%)

AMD

AMD

$39.61

-0.02 (-0.05%)

DOCU

DocuSign

$75.67

6.16 (8.86%)

MDCA

MDC Partners

$2.53

0.17 (7.20%)

GTT

GTT Communications

$11.31

0.805 (7.66%)

MTZ

MasTec

$62.49

-0.4 (-0.64%)

VRNS

Varonis

$76.40

-0.32 (-0.42%)

CHTR

Charter

$467.92

1.26 (0.27%)

OPRA

Opera

$9.18

0.13 (1.44%)

CCOI

Cogent

$61.66

-0.36 (-0.58%)

WWE

WWE

$63.26

0.97 (1.56%)

VIA

Use VIAC, VIACA

$25.99

(0.00%)

CONE

CyrusOne

$64.07

-0.16 (-0.25%)

MTCH

Match Group

$67.88

-0.22 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 11

    Dec

  • 12

    Dec

  • 16

    Dec

  • 17

    Dec

  • 31

    Jan

MSFT

Microsoft

$151.77

1.85 (1.23%)

08:00
12/09/19
12/09
08:00
12/09/19
08:00
Options
Microsoft call buyer realizes 11% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

OTSKY

Otsuka

$0.00

(0.00%)

07:59
12/09/19
12/09
07:59
12/09/19
07:59
Initiation
Otsuka initiated  »

Otsuka initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNRL

Brigham Minerals

$19.68

0.9 (4.79%)

07:59
12/09/19
12/09
07:59
12/09/19
07:59
Syndicate
Brigham Minerals files to sell 11M shares of common stock »

The Company is offering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHGCY

Chugai Pharmaceutical

$0.00

(0.00%)

07:58
12/09/19
12/09
07:58
12/09/19
07:58
Initiation
Chugai Pharmaceutical initiated  »

Chugai Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KYKOF

Kyowa Kirin

$0.00

(0.00%)

07:57
12/09/19
12/09
07:57
12/09/19
07:57
Initiation
Kyowa Kirin initiated  »

Kyowa Kirin initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNR

Pentair

$44.80

0.335 (0.75%)

07:57
12/09/19
12/09
07:57
12/09/19
07:57
Recommendations
Pentair analyst commentary  »

Pentair price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

DSNKY

Daiichi Sankyo

$0.00

(0.00%)

07:56
12/09/19
12/09
07:56
12/09/19
07:56
Initiation
Daiichi Sankyo initiated  »

Daiichi Sankyo initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

07:55
12/09/19
12/09
07:55
12/09/19
07:55
Conference/Events
Agios Pharmaceuticals to hold an investor reception »

Management hosts an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

ARQL

ArQule

$9.67

0.15 (1.58%)

07:55
12/09/19
12/09
07:55
12/09/19
07:55
Conference/Events
ArQule to hold an investor conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

THRM

Gentherm

$44.25

0.4 (0.91%)

07:54
12/09/19
12/09
07:54
12/09/19
07:54
Initiation
Gentherm initiated  »

Gentherm resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TJX

TJX

$59.85

0.28 (0.47%)

07:53
12/09/19
12/09
07:53
12/09/19
07:53
Recommendations
TJX analyst commentary  »

TJX price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ISTR

Investar Holding

$25.55

0.73 (2.94%)

07:51
12/09/19
12/09
07:51
12/09/19
07:51
Downgrade
Investar Holding rating change  »

Investar Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBK

FB Financial

$39.58

0.86 (2.22%)

07:50
12/09/19
12/09
07:50
12/09/19
07:50
Downgrade
FB Financial rating change  »

FB Financial downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$353.99

8.295 (2.40%)

07:49
12/09/19
12/09
07:49
12/09/19
07:49
Recommendations
Boeing analyst commentary  »

Boeing price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$233.74

0.3 (0.13%)

, BGNE

BeiGene

$186.89

-2.3 (-1.22%)

07:47
12/09/19
12/09
07:47
12/09/19
07:47
Recommendations
Amgen, BeiGene analyst commentary  »

Amgen price target raised…

AMGN

Amgen

$233.74

0.3 (0.13%)

BGNE

BeiGene

$186.89

-2.3 (-1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 27

    Feb

AMTD

TD Ameritrade

$51.12

0.32 (0.63%)

, SCHW

Charles Schwab

$48.95

0.22 (0.45%)

07:45
12/09/19
12/09
07:45
12/09/19
07:45
Downgrade
TD Ameritrade, Charles Schwab rating change  »

TD Ameritrade shares…

AMTD

TD Ameritrade

$51.12

0.32 (0.63%)

SCHW

Charles Schwab

$48.95

0.22 (0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

International Flavors

$142.03

0.21 (0.15%)

, DD

DuPont

$63.60

1.6 (2.58%)

07:45
12/09/19
12/09
07:45
12/09/19
07:45
Recommendations
International Flavors, DuPont analyst commentary  »

International Flavors…

IFF

International Flavors

$142.03

0.21 (0.15%)

DD

DuPont

$63.60

1.6 (2.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBIO

Mustang Bio

$3.86

0.025 (0.65%)

07:44
12/09/19
12/09
07:44
12/09/19
07:44
Hot Stocks
Mustang Bio: Lentiviral gene therapy with busulfan conditioning 'well tolerated' »

Mustang Bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

07:44
12/09/19
12/09
07:44
12/09/19
07:44
Recommendations
Bluebird Bio analyst commentary  »

Bluebird Bio price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

AM

Antero Midstream

$4.49

-0.025 (-0.55%)

, AR

Antero Resources

$2.18

0.09 (4.31%)

07:43
12/09/19
12/09
07:43
12/09/19
07:43
Hot Stocks
Antero Midstream to purchase $100M of shares from Antero Resources »

Antero Midstream (AM)…

AM

Antero Midstream

$4.49

-0.025 (-0.55%)

AR

Antero Resources

$2.18

0.09 (4.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCN

FTI Consulting

$111.68

0.28 (0.25%)

07:42
12/09/19
12/09
07:42
12/09/19
07:42
Hot Stocks
FTI Consulting enters partnership with Brainspace »

FTI Consulting announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBIO

BridgeBio

$33.03

0.8 (2.48%)

07:41
12/09/19
12/09
07:41
12/09/19
07:41
Hot Stocks
BridgeBio appoints Eli Wallace as chief scientific officer for oncology »

BridgeBio Pharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

07:40
12/09/19
12/09
07:40
12/09/19
07:40
Recommendations
Alphabet Class A analyst commentary  »

Alphabet shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:40
12/09/19
12/09
07:40
12/09/19
07:40
General news
Treasury Market Outlook: equities have dipped lower in quiet trade »

Treasury Market Outlook:…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.